These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11133779)

  • 21. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
    Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
    Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
    Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
    Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adeno-associated virus-mediated expression of β-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain.
    Sargeant TJ; Wang S; Bradley J; Smith NJ; Raha AA; McNair R; Ziegler RJ; Cheng SH; Cox TM; Cachón-González MB
    Hum Mol Genet; 2011 Nov; 20(22):4371-80. PubMed ID: 21852247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic correction in microglia derived from Sandhoff disease model mice.
    Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Itoh K
    J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biology and potential strategies for the treatment of GM2 gangliosidoses.
    Chavany C; Jendoubi M
    Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substrate reduction therapy in mouse models of the glycosphingolipidoses.
    Platt FM; Jeyakumar M; Andersson U; Heare T; Dwek RA; Butters TD
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):947-54. PubMed ID: 12803928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.
    Walia JS; Altaleb N; Bello A; Kruck C; LaFave MC; Varshney GK; Burgess SM; Chowdhury B; Hurlbut D; Hemming R; Kobinger GP; Triggs-Raine B
    Mol Ther; 2015 Mar; 23(3):414-22. PubMed ID: 25515709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of enzyme-bearing cells in GM2 gangliosidosis mice: regionally specific pattern of cellular infiltration following bone marrow transplantation.
    Oya Y; Proia RL; Norflus F; Tifft CJ; Langaman C; Suzuki K
    Acta Neuropathol; 2000 Feb; 99(2):161-8. PubMed ID: 10672323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
    Tsuji D; Kuroki A; Ishibashi Y; Itakura T; Kuwahara J; Yamanaka S; Itoh K
    J Neurochem; 2005 Mar; 92(6):1497-507. PubMed ID: 15748167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
    Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
    Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
    Andersson U; Butters TD; Dwek RA; Platt FM
    Biochem Pharmacol; 2000 Apr; 59(7):821-9. PubMed ID: 10718340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Miglustat therapy in juvenile Sandhoff disease.
    Tallaksen CM; Berg JE
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S289-93. PubMed ID: 19898953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder.
    Liu Y; Wada R; Kawai H; Sango K; Deng C; Tai T; McDonald MP; Araujo K; Crawley JN; Bierfreund U; Sandhoff K; Suzuki K; Proia RL
    J Clin Invest; 1999 Feb; 103(4):497-505. PubMed ID: 10021458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts.
    Arfi A; Bourgoin C; Basso L; Emiliani C; Tancini B; Chigorno V; Li YT; Orlacchio A; Poenaru L; Sonnino S; Caillaud C
    Neurobiol Dis; 2005 Nov; 20(2):583-93. PubMed ID: 15953731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol.
    Bourgoin C; Emiliani C; Kremer EJ; Gelot A; Tancini B; Gravel RA; Drugan C; Orlacchio A; Poenaru L; Caillaud C
    Gene Ther; 2003 Oct; 10(21):1841-9. PubMed ID: 12960974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
    Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
    Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta.
    Arfi A; Zisling R; Richard E; Batista L; Poenaru L; Futerman AH; Caillaud C
    J Neurochem; 2006 Mar; 96(6):1572-9. PubMed ID: 16441513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
    Kaidonis X; Byers S; Ranieri E; Sharp P; Fletcher J; Derrick-Roberts A
    Mol Genet Metab; 2016 Jun; 118(2):100-10. PubMed ID: 27106513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
    Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
    Butters TD; Dwek RA; Platt FM
    Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.